Angiogenesis
Angiogenesis inhibitors are compounds that interfere with the formation of new blood vessels, a process critical in cancer growth and metastasis. By inhibiting angiogenesis, these compounds can restrict the blood supply to tumors, slowing or halting their growth. Angiogenesis inhibitors are essential in cancer research and therapeutic development, providing insights into the mechanisms of tumor progression and offering potential treatments for cancer and other angiogenesis-related diseases. At CymitQuimica, we offer a wide range of high-quality angiogenesis inhibitors to support your research in oncology and vascular biology.
Subcategories of "Angiogenesis"
- BTK(159 products)
- Bcr-Abl(115 products)
- EGFR(593 products)
- FAK(72 products)
- FLT(89 products)
- Fibroblast Growth Factor Receptor (FGFR)(182 products)
- JAK(246 products)
- PDGFR(126 products)
- RAAS(90 products)
- Src(81 products)
- Syk(37 products)
- Thrombin(53 products)
- VDA(2 products)
- VEGFR(247 products)
Show 6 more subcategories
Found 2121 products of "Angiogenesis"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Pirtobrutinib
CAS:Pirtobrutinib: a selective, non-covalent BTK inhibitor effective against BTK C481 mutations, causing tumor regression in lymphoma models.Formula:C22H21F4N5O3Purity:99.76% - 99.94%Color and Shape:SolidMolecular weight:479.43ALK/EGFR-IN-2
CAS:ALK/EGFR-IN-2 is a potent dual inhibitor targeting ALK and EGFR, promoting apoptosis and G0/G1 cell cycle arrest in cancer cells.Formula:C27H34ClN7O3SColor and Shape:SolidMolecular weight:572.12YS-363
CAS:<p>YS-363 is a potent, selective, and orally active inhibitor of the epidermal growth factor receptor (EGFR), exhibiting half-maximal inhibitory concentrations (</p>Formula:C30H30N4O3Purity:98%Color and Shape:SolidMolecular weight:494.58TAK-659
CAS:TAK-659 is a spleen tyrosine kinase (SYK) inhibitor.Formula:C17H21FN6OPurity:98%Color and Shape:SolidMolecular weight:344.39EGFR-IN-71
CAS:<p>EGFR-IN-71 is a potent inhibitor of epidermal growth factor receptor (EGFR) (IC50= 3.7 μM). EGFR-IN-71 has research value in chordoma.</p>Formula:C16H9ClIN3Color and Shape:SolidMolecular weight:405.62EGFR-IN-74
EGFR-IN-74 is a potent inhibitor targeting EGFR, specifically effective against the L858R/T790M mutations, exhibiting an IC50 value of 138 nM.Formula:C32H28BrF3N6O4SColor and Shape:SolidMolecular weight:729.57T338C Src-IN-1
CAS:T338C Src-IN-1 is a potent mutant-Src T338C inhibitor(T338C,IC50=111 nM relative to WT c-Src (10-fold increase)).Formula:C17H20N6O2SPurity:98%Color and Shape:SolidMolecular weight:372.44FLT3-IN-14
CAS:FLT3-IN-14: FLT3 inhibitor; FLT3-WT IC50=5.6nM, FLT3-ITD IC50=1.4nM; blocks Y591 phosphorylation; G1 arrest; pro-apoptotic.Formula:C25H24N6O2SColor and Shape:SolidMolecular weight:472.56PAT-505
CAS:PAT-505 is an autologous epidermal growth factor inhibitor.Formula:C23H18ClF2N3O2SPurity:98.84%Color and Shape:SolidMolecular weight:473.92MTP
CAS:MTP, a PKM2 inhibitor, promotes apoptosis in cancer cells via caspase-3 activation while also inducing autophagy and enhancing ROS generation.Formula:C29H23F3N4O2Purity:98%Color and Shape:SolidMolecular weight:516.51Nazartinib S-enantiomer
CAS:Nazartinib is an EGFR inhibitor. Nazartinib S-enantiomer is the less active S-enantiomer of Nazartinib.Formula:C26H31ClN6O2Purity:98%Color and Shape:SolidMolecular weight:495.02JAK-IN-1
CAS:JAK-IN-1 shows improved selectivity for JAK3 over JAK1. JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively.Formula:C20H24N6O2Purity:98%Color and Shape:SolidMolecular weight:380.44PonatiLink-1-24
CAS:Ponatinib, also known as PonatiLink-1-24, is a selective inhibitor of the Abelson murine leukemia (ABL) enzyme [1].Formula:C101H144ClF5N12O29Color and Shape:SolidMolecular weight:2120.73JGK-068S
CAS:Compound I (JGK-068S) is a potent inhibitor of the epidermal growth factor receptor (EGFR) [1].Formula:C22H23BrFN5O2Purity:98%Color and Shape:SolidMolecular weight:488.35TIE-2/VEGFR-2 kinase-IN-4
CAS:TIE-2/VEGFR-2 kinase-IN-4, a benzimidazole derivative, serves as a potent inhibitor of the tyrosine kinase receptors TIE-2 and VEGFR-2, exhibiting inhibitoryFormula:C26H17F4N5O4Color and Shape:SolidMolecular weight:539.44ALK/ROS1-IN-1
CAS:ALK/ROS1-IN-1 is a potent and selective anti-crizotinib-resistant ALK/ROS1 dual inhibitor (IC50s: 0.530 μM and 0.174 μM for ROS1 and ALK enzyme).Formula:C30H35F3N6O3Purity:98%Color and Shape:SolidMolecular weight:584.63JAK-IN-4
CAS:JAK-IN-4 is a prodrug of a JAK inhibitor, effective in murine collagen induced arthritis model.Formula:C18H21N4Na2O6PPurity:98%Color and Shape:SolidMolecular weight:466.341JND3229
CAS:JND3229 inhibits EGFRC797S; IC50: 5.8-30.5 nM; halts cell growth; effective in non-small cell lung cancer study.Formula:C33H41ClN8O2Purity:98.75%Color and Shape:SolidMolecular weight:617.18EGFR-IN-85
CAS:EGFR-IN-85 (Compound 1), an EGFR inhibitor, exhibits potent activity with an IC50 of 0.19 μM against EGFRvⅢ phosphorylation and can suppress intratumoral EGFRFormula:C26H30N8O2Purity:98%Color and Shape:SolidMolecular weight:486.57EGFR mutant-IN-1
EGFR mutant-in-1, a 5-methylpyrimidopyridone, selectively inhibits EGFRL858R/T790M/C797S mutants with an IC50 of 27.5 nM, lessening EGFRWT impact.Formula:C34H39ClFN7O2Purity:98%Color and Shape:SolidMolecular weight:632.17EGFR kinase inhibitor 1
CAS:Potent EGFR blocker; acts on WT, L858R/T790M (IC50: 1.7 nM), less on T790M/C797S; stalls cell cycle, induces apoptosis, deters metastasis.Formula:C30H31N7O2Color and Shape:SolidMolecular weight:521.61ALK/EGFR-IN-1
CAS:ALK/EGFR-IN-1 (Compound 8l) is a dual inhibitor targeting both ALK and EGFR, effectively blocking their phosphorylation.Formula:C27H34ClN7O3SPurity:98%Color and Shape:SolidMolecular weight:572.12Ruxolitinib sulfate
CAS:Ruxolitinib sulfate, a potent JAK1/2 inhibitor (IC50: 3.3/2.8 nM), is >130x more selective for JAK1/2 than JAK3.Formula:C17H20N6O4SColor and Shape:SolidMolecular weight:404.45Ifebemtinib
CAS:Ifebemtinib (BI-853520) is an adhesion plaque kinase inhibitor with anti-tumour activity for the study of breast cancer.Formula:C28H28F4N6O4Purity:98.84% - 99.85%Color and Shape:SolidMolecular weight:588.55CH6953755
CAS:CH6953755: oral YES1 kinase inhibitor, IC50 1.8 nM, potent, selective, anticancer, halts cell proliferation.Formula:C26H22F2N6O4SPurity:98.87%Color and Shape:SolidMolecular weight:552.55TAK-020
CAS:TAK-020 is a potent covalent inhibitor of Btk with potential antitumor activity for the study of rheumatoid arthritis and immune-related diseases.Formula:C18H17N5O3Purity:98.66%Color and Shape:SolidMolecular weight:351.36WAY-600
CAS:WAY-600 is a potent, ATP-competitive and selective inhibitor of mTOR with IC50 of 9 nM; blocks mTORC1/P-S6K(T389) and mTORC2/P-AKT(S473) but not P-AKT(T308).Formula:C28H30N8OPurity:99.88%Color and Shape:SolidMolecular weight:494.59Zongertinib
CAS:Zongertinib is a human HER2-selective tyrosine kinase inhibitor, a novel TK that is highly selective for covalent binding to the HER2 tyrosine kinase domain (Formula:C29H29N9O2Purity:98.24%Color and Shape:SolidMolecular weight:535.6EGFR-IN-87
CAS:EGFR-IN-87 is an EGFR tyrosine kinase inhibitor with potent inhibitory activity, exhibiting IC50 values of 3.1 nM, 1.3 nM, and 7.1 nM against EGFR_d746-750,Formula:C28H33N7O2Purity:98.64%Color and Shape:SolidMolecular weight:499.61IN-1130
CAS:IN-1130: ALK5 inhibitor, IC50 - 5.3 nM (Smad3), 36 nM (casein), 4.3 μM (p38α MAPK).Formula:C25H20N6OPurity:99.79%Color and Shape:SolidMolecular weight:420.47BMS-935177
CAS:BMS-935177 is a reversible BTK inhibitor with IC50 value of 3 nM.Formula:C31H26N4O3Purity:99.89%Color and Shape:SolidMolecular weight:502.56Sevabertinib
CAS:Sevabertinib (BAY 2927088) is an EGFR tyrosine kinase inhibitor, with anticancer activity, used in research on non-small cell lung cancer.Formula:C24H25ClN4O5Purity:99.81%Color and Shape:SolidMolecular weight:484.93KER047
CAS:ALK2-IN-4, a highly effective ALK2 inhibitor.Formula:C26H30FN7OPurity:98.49% - >99.99%Color and Shape:SolidMolecular weight:475.56ALK-IN-27
CAS:Neladalkib (NVL-655) is an ALK inhibitor with antitumor activity for the study of non-small cell cancers.Formula:C23H22ClFN6OPurity:99.71%Color and Shape:SolidMolecular weight:452.91EGFR-IN-1 hydrochloride
CAS:EGFR-IN-1 HCl targets L858R/T790M EGFR mutants over wild-type; IC50: 4 nM in H1975, 28 nM in mutant HCC827 cells.Formula:C28H31ClN6O4Purity:99.16%Color and Shape:SolidMolecular weight:551.04CAY10781
CAS:CAY10781 inhibits NRP-1/VEGF-A binding by 43% at 12.5μM and blocks VEGFR2 phosphorylation in CAD cells.Formula:C11H9N3O3Purity:99.49%Color and Shape:SolidMolecular weight:231.21HM43239
CAS:HM43239: oral FLT3 inhibitor; IC50: FLT3 WT 1.1nM, ITD 1.8nM, D835Y 1.0nM; blocks p-STAT5/p-ERK; affects SYK, JAK1/2, TAK1; halts leukemia cell growth.Formula:C29H33ClN6Purity:99.7%Color and Shape:SolidMolecular weight:501.07Src Inhibitor 3
CAS:Src Inhibitor 3 blocks c-Src kinase (IC50 <3 nM CSK HTRF, <4 nM Caliper), boosting T cell growth from receptor signals.Formula:C34H32ClFN8O4Purity:98.35%Color and Shape:SolidMolecular weight:671.12EGFR-IN-130
EGFR-IN-130 (compound 14b) is an EGFR inhibitor and an inducer of apoptosis (apoptoosis). It effectively kills HeLa cancer cells by inducing apoptosis.Formula:C27H25N3O6SColor and Shape:SolidMolecular weight:519.57VEGFR-2-IN-25
CAS:VEGFR-2-IN-25 (compound 5d) is a potent inhibitor of VEGFR-2 (IC50: 12.1 nM).Formula:C24H22N6O2Color and Shape:SolidMolecular weight:426.47HER2-IN-8
CAS:HER2-IN-8 is an inhibitor of HER-2 that can be used in the study of cancer and inflammation-related diseases.Formula:C26H25F2N9O3Color and Shape:SolidMolecular weight:549.53EGFR/HER2-IN-8
EGFR/HER2-IN-8 inhibits EGFR, HER2, DHFR (IC50: 0.45, 0.244, 5.669 μM); useful in cancer research, safe and selective.Formula:C16H16N4O2SColor and Shape:SolidMolecular weight:328.39OXA-11
CAS:OXA-11 (FAK-IN-16) is a FAK inhibitor with anti-tumor activity, useful for cancer research.Formula:C37H49F3N7O5PPurity:98.70% - 99.20%Color and Shape:SolidMolecular weight:759.8CGP062464
CAS:CGP062464 is an inhibitor of the tyrosine kinase c-Src, with an IC50 of less than 50 nM. It is utilized in research related to osteoporosis and tumor-induced hypercalcemia.Formula:C18H14N4Color and Shape:SolidMolecular weight:286.331DDO-02267
CAS:<p>DDO-02267 is a selective lysine-targeted covalent inhibitor of ALKBH5, with an IC50 value of 0.49 μM. It increases levels of N6-methyladenosine (m6A) and targets the ALKBH5-AXL signaling axis. DDO-02267 serves as a probe for studying the biological function of mRNA demethylases.</p>Formula:C18H12N2O7SColor and Shape:SolidMolecular weight:400.362FLT3/TrKA-IN-1
FLT3/TrKA-IN-1: Potent dual kinase inhibitor for FLT3 & TrKA, promising for AML research.Formula:C28H30N4O2Color and Shape:SolidMolecular weight:454.56Multi-kinase-IN-1
CAS:Multi-kinase-IN-1, a powerful kinase inhibitor, exhibits antitumor properties by inducing cell apoptosis.Formula:C35H36F2N6O6SColor and Shape:SolidMolecular weight:706.76BTK-IN-32
CAS:BTK-IN-32 (compound C2) acts as a potent BTK inhibitor. Unlike isolated kinase domains, this compound activates full-length BTK as well as its smaller multidomain fragments [1].Formula:C35H35ClN4O3SMolecular weight:627.2EGFR-IN-45
EGFR-IN-45: Strong EGFR/CDK2 inhibitor (IC50s: 0.4 & 1.6 μM), halts cancer cell cycle pre-G1, prompts apoptosis, also targets Topo I/II.Formula:C28H23N7OColor and Shape:SolidMolecular weight:473.53VEGFR-2-IN-12
VEGFR-2-IN-12 (compound 6g), a 2-oxoquinoxalinyl-1,2,4-triazole, is a potent inhibitor of VEGFR-2 (IC50: 0.037 μM). VEGFR-2-IN-12 has anti-tumour effects.Formula:C22H24N6O3SColor and Shape:SolidMolecular weight:452.53
